Oldham A A, Arnstein M J, Major J S, Clough D P
J Hypertens. 1984 Apr;2(2):157-61. doi: 10.1097/00004872-198404000-00006.
The specificity of pepstatin A as an inhibitor of the cardiovascular actions of renin injected into anaesthetized rats has been investigated. Pepstatin A 70 micrograms/kg/min partially inhibited the pressor response to injected renin without affecting the pressor responses to injected angiotensin II, phenylephrine or vasopressin. Pepstatin A 150 micrograms/kg/min also produced partial inhibition of injected renin, but in addition caused significant inhibition of the other pressor agents. This was in contrast to the effects of the angiotensin converting enzyme inhibitor captopril, 100 micrograms/kg i.v., which caused greater inhibition of the renin pressor response than pepstatin A without affecting the pressor response to injected angiotensin II, phenylephrine or vasopressin. Finally the direct acting vasodilator hydralazine was found to have a similar non-specific inhibitory effect to pepstatin A on the pressor responses to injected pressor agents. It is concluded that pepstatin A reduces the pressor responsiveness to injected pressor agents and that this non-specific cardiovascular activity limits the usefulness of pepstatin A as a pharmacological tool to inhibit renal renin in vivo.
已对胃蛋白酶抑制剂A作为注入麻醉大鼠体内的肾素心血管作用抑制剂的特异性进行了研究。胃蛋白酶抑制剂A以70微克/千克/分钟的剂量部分抑制了对注入肾素的升压反应,而不影响对注入血管紧张素II、去氧肾上腺素或血管加压素的升压反应。胃蛋白酶抑制剂A以150微克/千克/分钟的剂量也部分抑制了注入的肾素,但此外还显著抑制了其他升压剂。这与血管紧张素转换酶抑制剂卡托普利(静脉注射100微克/千克)的作用形成对比,卡托普利对肾素升压反应的抑制作用比胃蛋白酶抑制剂A更强,且不影响对注入血管紧张素II、去氧肾上腺素或血管加压素的升压反应。最后发现,直接作用的血管扩张剂肼屈嗪对注入升压剂的升压反应具有与胃蛋白酶抑制剂A类似的非特异性抑制作用。得出的结论是,胃蛋白酶抑制剂A降低了对注入升压剂的升压反应性,并且这种非特异性心血管活性限制了胃蛋白酶抑制剂A作为体内抑制肾素的药理学工具的实用性。